



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_68_25

You asked:

How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Etrasimod
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab - Stelara
- Ustekinumab Biosimilar
- Vedolizumab

Our response:

Please see table below populated with the information Medicines Management are able to provide at this current time. The period the data relates to 1st November 2024 to 31st January 2025 (the latest 3 months available).

Medicine	Number of Patients
Adalimumab - Humira	**
Adalimumab Biosimilar	217
Etrasimod	0
Filgotinib	0
Golimumab	0
Infliximab - Remicade	**
Infliximab Biosimilar	234
Mirikizumab	0
Ozanimod	**
Risankizumab	28
Tofacitinib	0
Upadacitinib	29

Ustekinumab - Stelara	129
Ustekinumab Biosimilar	40
Vedolizumab	198

Where the figures are less than 5, this has been denoted by **.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain.

In our view disclosure of these low figures would breach the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.